Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Notes Payables (2023 - 2025)

Historic Notes Payables for Evoke Pharma (EVOK) over the last 3 years, with Q3 2025 value amounting to $5.0 million.

  • Evoke Pharma's Notes Payables changed 0.0% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.0 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Notes Payables is $5.0 million, which was down 0.0% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Evoke Pharma's Notes Payables peaked at $5.0 million during Q2 2023, and registered a low of $5.0 million during Q2 2023.
  • Moreover, its 3-year median value for Notes Payables was $5.0 million (2023), whereas its average is $5.0 million.
  • The largest annual percentage gain for Evoke Pharma's Notes Payables in the last 5 years was 0.0% (2024), contrasted with its biggest fall of 0.0% (2024).
  • Evoke Pharma's Notes Payables (Quarter) stood at $5.0 million in 2023, then changed by 0.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
  • Its Notes Payables stands at $5.0 million for Q3 2025, versus $5.0 million for Q2 2025 and $5.0 million for Q1 2025.